Published in Physician Law Weekly, August 23rd, 2006
On a reported basis under U.S. Generally Accepted Accounting Principles (GAAP), Celgene reported net income of $9.6 million, or diluted earnings per share of $0.03, including share-based employee compensation expense, compared to net income in the prior year period of $10.8 million. Total revenue was a record $197.2 million for the quarter ended June 30, 2006, an increase of 35.4% (56.8% excluding a one-time milestone payment) over the same period in 2005 driven by strong Revlimid net sales of $63.0 million, and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly